Related Experiment Video
Updated: Dec 18, 2025

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses
Published on: November 10, 2023
A snapshot of the ongoing clinical research on COVID-19
Daniele Piovani1,2, Claudia Pansieri1,2, Laurent Peyrin-Biroulet3
1Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, 20090, Italy.
Abstract:
The pandemic of coronavirus disease 2019 (COVID-19) presents an unprecedented challenge to rapidly develop new diagnostic, preventive and therapeutic strategies. Currently, thousands of new COVID-19 patients are quickly enrolled in clinical studies. We aimed to investigate the characteristics of the COVID-19 studies registered in ClinicalTrials.gov and report the extent to which they have incorporated features that are desirable for generating high-quality evidence. On April 28, 2020, a total of 945 studies on COVID-19 have been registered in ClinicalTrials.gov; 586 studies are interventional (62.0%), the most frequent allocation scheme is the parallel group assignment (437; 74.6%), they are open-label and the most common primary purpose is the research on treatment. Too many of the ongoing interventional studies have a small expected sample size and may not generate credible evidence at completion. This might lead to a delayed recognition of effective therapies that are urgently needed, and a waste of time and resources. In the COVID-19 pandemic era, it is crucial that the adoption of new diagnostic, preventive and therapeutic strategies is based upon evidence coming from well-designed, adequately powered and carefully conducted clinical trials.
Insights
Clinical trials for coronavirus disease 2019 (COVID-19) show many interventional studies have small sample sizes, potentially hindering the discovery of effective treatments. Ensuring well-designed, adequately powered trials is crucial for evidence-based strategies.
Area of Science:
- Clinical trial design
- Epidemiology
- Public health
Background:
- The COVID-19 pandemic necessitates rapid development of diagnostic, preventive, and therapeutic strategies.
- Thousands of patients are enrolled in clinical studies during the pandemic.
Purpose of the Study:
- To investigate the characteristics of COVID-19 studies registered in ClinicalTrials.gov.
- To assess the incorporation of features desirable for high-quality evidence generation in these studies.
Main Methods:
- Analysis of 945 COVID-19 studies registered in ClinicalTrials.gov as of April 28, 2020.
- Categorization of studies by type, allocation scheme, blinding, and primary purpose.
Main Results:
- 586 (62.0%) studies were interventional, with parallel group assignment being the most frequent (74.6%).
- Most interventional studies were open-label, with treatment research as the primary purpose.
- A significant number of interventional studies had small expected sample sizes, potentially compromising evidence credibility.
Conclusions:
- Many ongoing COVID-19 interventional studies may not generate credible evidence due to inadequate sample sizes.
- This could delay the identification of effective therapies and waste resources.
- Well-designed, adequately powered clinical trials are essential for evidence-based decision-making during the COVID-19 pandemic.
More Related Videos
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Preclinical Development: Overview
Study Designs in Epidemiology
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History

